Analyst Price Targets — MNPR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 9, 2026 10:11 am | Maxwell Skor | Morgan Stanley | $115.00 | $63.40 | TheFly | Monopar Therapeutics initiated with an Overweight at Morgan Stanley |
| November 14, 2025 10:06 am | Chris Raymond | Raymond James | $123.00 | $87.01 | StreetInsider | Raymond James Downgrades Monopar Therapeutics (MNPR) to Outperform |
| October 13, 2025 9:25 am | Etzer Darout | Barclays | $125.00 | $87.82 | TheFly | Monopar Therapeutics initiated with an Overweight at Barclays |
| October 6, 2025 11:26 am | — | Raymond James | $142.00 | $99.39 | TheFly | Monopar Therapeutics price target raised to $142 from $80 at Raymond James |
| October 2, 2025 11:50 am | — | Oppenheimer | $115.00 | $84.73 | TheFly | Monopar Therapeutics price target raised to $115 from $77 at Oppenheimer |
| September 29, 2025 12:13 pm | — | H.C. Wainwright | $105.00 | $76.63 | TheFly | Monopar Therapeutics price target raised to $105 from $70 at H.C. Wainwright |
| September 25, 2025 11:55 am | Keay Nakae | Chardan Capital | $85.00 | $72.70 | TheFly | Monopar Therapeutics price target raised to $85 from $60 at Chardan |
| September 25, 2025 10:28 am | Biren Amin | Piper Sandler | $95.00 | $72.70 | TheFly | Monopar Therapeutics price target raised to $95 from $76 at Piper Sandler |
| September 24, 2025 8:05 pm | — | BTIG | $104.00 | $73.04 | TheFly | Monopar Therapeutics price target raised to $104 from $87 at BTIG |
| September 9, 2025 10:37 am | Jeet Mukherjee | BTIG | $87.00 | $44.93 | TheFly | Monopar Therapeutics initiated with a Buy at BTIG |
Latest News for MNPR
WILMETTE, Ill. , April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in…
WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in…
WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments.
Ally Bridge Group NY LLC increased its position in shares of Monopar Therapeutics Inc. (NASDAQ: MNPR) by 86.6% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 64,455 shares of the company's stock after purchasing an additional 29,918 shares during the period.
WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MNPR.
U.S. House Trading
No House trades found for MNPR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.